Ready for ctDNA-guided treatment decisions in colorectal cancer?

Affiliations

Jiaolin Zhou et al. J Natl Cancer Cent. 2022.

. 2022 Nov 10;3(1):1-3.

doi: 10.1016/j.jncc.2022.10.003. eCollection 2023 Mar.

¹ Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.

No abstract available

Conflict of interest statement

The authors declare that they have no conflict of interests.

Exosomes derived from cancer-associated fibroblasts promote tumorigenesis, metastasis and chemoresistance of colorectal cancer by upregulating circ_0067557 to target Lin28.
Yang C, Zhang Y, Yan M, Wang J, Wang J, Wang M, Xuan Y, Cheng H, Ma J, Chai C, Li M, Yu Z. Yang C, et al. BMC Cancer. 2024 Jan 12;24(1):64. doi: 10.1186/s12885-023-11791-5. BMC Cancer. 2024. PMID: 38216964 Free PMC article.

1. Ryan B.M., Lefort F., McManus R., et al. A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up. Gut. 2003;52(1):101–108. - PMC - PubMed
1. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–990. - PMC - PubMed
1. Reinert T., Henriksen T.V., Christensen E., et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131. - PMC - PubMed
1. Tarazona N., Gimeno-Valiente F., Gambardella V., et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. Ann Oncol. 2019;30(11):1804–1812. - PubMed
1. Tie J., Cohen J.D., Lahouel K., et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261–2272. - PMC - PubMed